BTK and B-cell chronic lymphocytic leukemia: Ibrutinib is a first-in-class selective and irreversible BTK inhibitor (BTKi) that inhibits CLL-associated cell signaling, adhesion, propagation, and homing in vitro and in vivo [19,20,21].